To appreciate the relevance of central stimulationbased interventions in MS treatment, we need to start from two basic principles of the neurobiology. First, synapses are highly plastic structures that easily respond and adapt to environmental stimulations, by fine-tuning their connectivity to their synaptic partners. Moreover, neurons can make synaptic contacts with other neurons that have lost part of their synapses in order to restore appropriate functioning of the circuitry and to avoid neuronal loss, thus playing a neuroprotective role. 2 Second, myelin formation and maintenance in the adult brain is a highly dynamic and complex process that continuously takes place to ensure the proper sheathing of axons and, more importantly, is tightly regulated by neuronal activity. 3 These simple neurobiological concepts of neuronal and myelin plasticity lay the ground for developing treatments for a neurological disorder like MS, where an early and progressive loss of synapses occurs in concomitance with demyelination. Therefore, neurons can be targeted to modulate neuronal circuitry and to promote remyelination, which, in fact, is a therapeutic strategy currently under investigation for MS treatment.
Introduction
In the last decades, the treatment of multiple sclerosis (MS) has made enormous progress. Diseasemodifying drugs are able to reduce the number of relapses and to slow the disease course, but still deserve the proper balancing of efficacy and safety. 1 The complexity and the heterogeneity of disease course and clinical symptoms of MS make compulsory the search for the appropriate personalized treatment and disease management, including non-pharmacological interventions, particularly in the progressive form of the disease.
The ultimate purpose of any form of rehabilitation is to ameliorate clinical symptoms by modulating neuronal activity. With this respect, the concept of rehabilitation in the context of MS has evolved from the classical motor rehabilitation to neuropsychological and cognitive therapy, peripheral stimulation, or non-invasive brain stimulation (NIBS) techniques, such as repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS).
In this review, we will consider preclinical studies addressing the neurobiological basis of rehabilitation in MS and of NIBS, as well as NIBS clinical applications on people with multiple sclerosis (pwMS). symptomatology linked to MS is supported by the quite recent recognition that the synaptic compartment is profoundly perturbated in MS at both structural and functional level and underlies the disease progression. 4 As extensively reviewed elsewhere, 5, 6 studies performed on different MS cohorts have clearly shown that cortical synaptic transmission, probed through several protocols of TMS, a non-invasive technique used to measure synaptic transmission in awake human subjects, 7 is altered in the brain of MS patients and that these changes correlate with measures of motor disability, like the Expanded Disability Status Scale (EDSS). In particular, measures of short-interval intracortical inhibition (SICI), indicative of GABAA interneuronal transmission, have been found significantly reduced in progressive multiple sclerosis (PMS) patients, 8 while the degree of the short-interval intracortical facilitation (SICF), a surrogate marker of glutamatergic transmission, was increased in relapsing-remitting multiple sclerosis (RRMS) patients and correlated with EDSS. 9 Moreover, TMS protocols of induction of long-term potentiation (LTP), the main form of synaptic plasticity in brain, have been used to assess cortical plasticity reserve, 6 in the light of the abovementioned concept of "neuroprotection" associated with physiological mechanisms of synaptic plasticity. 2 Interestingly, these studies have underscored that LTP-like plasticity was almost completely absent in primary-progressive multiple sclerosis (PPMS) patients, while it was significantly pronounced in stable RRMS subjects. 10 These data have led to the idea that the LTP-like expression in MS patients underlies distinct neuropathological processes and, as a consequence, different disease progressions.
Preclinical models to study therapeutic mechanisms of rehabilitation in MS
Although with some limitations, mainly linked to the difficulty to reproduce the whole range of clinical manifestations and neuropathological progression of human disease, animal models of MS offer the unique opportunity to investigate the pathophysiology of MS and the effects of pharmacological and non-pharmacological therapies for human MS at cellular and molecular level. Investigations in the experimental autoimmune encephalomyelitis (EAE), the best studied animal model of MS, have contributed to finely portray the synaptic changes, collectively called synaptopathy, occurring during the autoimmune attack, supporting findings in human MS brains. 4 Singleneuron electrophysiological experiments in several brain areas of EAE mice, namely, the striatum, the cerebellum, and the hippocampus, have shown an increased glutamatergic tone and a reduced GABAergic transmission. Also, like in the human MS cortex, hippocampal LTP in EAE was shown potentiated as the consequence of the loss of the inhibitory tone. 4, 6 Notably, preclinical studies in EAE mice have demonstrated that, independently of their immunomodulatory action, disease-modifying treatments (DMTs) can target the synaptopathy associated with EAE/MS brains, 4 supporting the idea that synaptopathy is a hallmark of EAE/MS brains and corroborating the use of EAE model to probe therapies for the treatment of MS. Similarly, physical exercise (forced or voluntary) and/or environmental enrichment (EE) have been demonstrated beneficial in counteracting the EAEassociated synaptopathy. 11 Exercise not only ameliorated EAE clinical symptoms but also recovered the sensitivity of cannabinoid receptor type 1 on GABA synapses, selectively downregulated during neuroinflammation, and rescued normal dendritic spines suggesting possible direct neuroprotective effects. 11 Moreover, prophylactic EE on juvenile mice improved clinical symptoms, preserved glutamate exocytosis efficiency from cortical terminals, and modified the levels of presynaptic proteins, suggesting that EE might act as a lifestyle positive modulator of EAE/ MS progression.
Principles of NIBS
Non-invasive transcranial brain stimulation, namely, tDCS and rTMS, is widely applied in neurorehabilitation and neuroplasticity research, for their capability of inducing changes in neural excitability outlasting the stimulation period and, with repeated sessions, in promoting synaptic changes in humans. 12 As rTMS and tDCS can influence neural activity in a frequencyor polarity-dependent manner, respectively, most applications in neurological deficits refer to excitatory NIBS (mainly high-frequency (HF) rTMS, e.g., >5 Hz, or anodal tDCS). Although little is known about NIBS application in preclinical MS models, clinical research applications in MS suggest its potential usefulness in a variety of symptoms that should prompt further validation as a recognized treatment strategy. In the following, we will review the applications of NIBS as a treatment for the most relevant MS symptoms ( Figure 1 ).
Pyramidal function
NIBS is able to modulate the presynaptic control on Ia sensory afferents mediating stretch reflex by facilitating or inhibiting the corticospinal pathways that normally exert spinal segmental control. 13 Nielsen et al. 14 first applied repetitive magnetic stimulation at the spinal level to treat spasticity in MS, reporting improvement in clinical spasticity scores and a longlasting depression of the soleus H-reflex, an electrophysiological measure of the stretch reflex. 15 In pwMS and lower limb spasticity, the effects of 1 Hz (inhibitory) and 5 Hz (excitatory) rTMS over the motor cortex of the more affected lower limb were compared. 16 Low-frequency rTMS increased, while 5 Hz rTMS decreased H/M amplitude ratio of the soleus H-reflex and increased corticospinal excitability. 16 Furthermore, a significant improvement of lower limb spasticity, measured with the Modified Ashworth Scale (MAS), was obtained when 5-Hz rTMS was repeated during a 2-week period. Clinical improvement was long-lasting, up to 1 week after the end of treatment. 16 Improvement of spasticity has been found also after intermittent transcranial magnetic theta burst stimulation (iTBS) [17] [18] [19] and correlated with changes in functional connectivity between the two primary motor cortices. 19 The effects of iTBS were significantly greater when combined with exercise therapy, suggesting that the association of these two strategies is a promising tool for motor rehabilitation. 18 Preliminary data also suggest that 3 weeks of treatment of HF-rTMS delivered with the H-coil targeting the leg motor areas bilaterally could improve walking abilities together with reducing spasticity in patients with PMS. 20 Korzhova et al. compared the effect of 10 daily sessions over 2 weeks of iTBS, HF (20 Hz) rTMS targeting the hand M1 of the left hemisphere and sham stimulation in 34 secondary-progressive multiple sclerosis (SPMS) subjects with spasticity. Both iTBS and HF-rTMS significantly ameliorated measures of spasticity with some evidence in favor of a longer-lasting effect (up to 12 weeks) of iTBS. Reduction of pain and fatigue was obtained only in the HF-rTMS group. 21 On the contrary, in a randomized study on 20 patients with spasticity, no significant clinical improvement was found after real or sham tDCS applied to the lower limb motor representation for 5 consecutive days. 22 Improvement in hand dexterity in pwMS and cerebellar symptoms after rTMS targeting M1 has been reported shortly after a single session 23 and up to 1 month after two consecutive sessions. 24 Also, 10 daily sessions of iTBS over the hand M1 were associated with significantly better improvement of manual dexterity compared with sham stimulation. 25 Anodal tDCS applied to M1 contralateral to the more severely impaired hand increased the corticospinal output and projection strength evaluated with the input/output curve, but no behavioral effects were measured. 26 
Fatigue
Fatigue is a very common symptom in MS, especially in the progressive course. Although peripheral mechanisms, such as metabolic muscle changes, may contribute to produce fatigue, a major role is played by "central" abnormalities. 27 Dysfunction of the brain circuits between thalamus, basal ganglia, and frontal cortex has been hypothesized. 28 Due to the complex pathophysiology of fatigue, several stimulation targets for NIBS have been tested, mainly using anodal tDCS. Bilateral tDCS over M1 has been applied for 5 days in 25 MS subjects with chronic fatigue in a cross-over study, with significant decrease in 65% of subjects after real versus 30% after sham stimulation; the effect persisted after 3 weeks. 29 Tecchio et al. 30, 31 obtained positive results applying anodal tDCS bilaterally over the whole somatosensory area. Anodal tDCS over the left dorsolateral prefrontal cortex (L-DLPFC) significantly ameliorated fatigue in two sham-controlled studies. 32, 33 In another study, the subgroup of subjects with high left frontal lesion load responded significantly to anodal tDCS, suggesting that individual anatomical and functional features may determine the effectiveness of different stimulation protocols. 34 Gaede et al. used the H-coil for comparing the effect of HF-rTMS over the left prefrontal cortex and bi-hemispheric primary motor areas on fatigue or depression. A significant amelioration of fatigue was obtained only after primary motor areas stimulation up to 12 weeks of follow-up. No effects were observed on depression symptom. 35 Finally, no effect on fatigue has been obtained from anodal tDCS of the right posterior parietal cortex. 32 Besides heterogeneity in clinical features of participants and stimulation site, inconsistent results obtained with tDCS may also be related to the relatively short intervention, from up to 5 days in most studies [29] [30] [31] [32] 34 to 20 days, 33 and the lack of a behavioral intervention.
Cognition
Cognitive impairment is a common symptom in MS with prevalence rates ranging from 43% to 70%. Attention, information processing efficiency, executive functioning, processing speed, and long-term memory are usually affected in MS subjects. 36 In a randomized study on 20 pwMS undergoing 10 sessions of cognitive training (CT) for impaired attention and information processing speed, concurrent anodal tDCS over the L-DLPFC was associated with a significantly greater neuropsychological improvement up to 6 months later. 37 In an open-label study, remotely supervised anodal tDCS has been reported effective in pwMS undergoing 10 sessions of at-home CT, with significantly greater improvement in complex attention and response variability composites compared with a control group undergoing CT only, while no significant differences were found in basic attention. 38 In a functional magnetic resonance imaging (MRI) study, changes in whole brain functional activation and connectivity have been found after a single session of 10-Hz rTMS over the right DLPFC before a visuospatial working memory task in MS. In particular, the accuracy in performing the visuospatial task improved after real rTMS and not after sham in patients. MS subjects showed higher task-related frontal activation than controls at baseline, which disappeared after real rTMS. Furthermore, task-related functional connectivity between the right DLPFC and the right caudate nucleus and bilateral (para-)cingulate increased significantly only after real rTMS. 39 Other symptoms Few data are available on application of NIBS for the treatment of other MS-related symptoms, such as pain, 40, 41 sensory deficits, 42 lower urinary tract dysfunction, 43 and dysphagia. 44 In 19 patients with RRMS with chronic neuropathic pain, anodal tDCS over the motor cortex contralateral to the painful body region for 5 consecutive days was associated with significantly greater pain improvement compared with sham, lasting up to 3 weeks. 40 In a more recent study, improvement of neuropathic pain has been obtained also after 10 daily sessions of spinal cord tDCS with effects persisting up to 1 month after the end of treatment. 41 In 10 subjects complaining of lower urinary tract symptoms, 5 consecutive days for 2 weeks of 5 Hz rTMS over the soleus motor cortex led to significant improvement of symptoms in the subgroup of six patients with detrusor underactivity. 43 In an open-label study on six patients, a 5-day course of anodal tDCS was followed by one point improvement in Dysphagia Outcome and Severity Scale persisting up to 1 month. 44 
Safety
As far as safety is concerned, both rTMS and tDCS present a reassuring profile. 45 Adverse events reported for rTMS, mainly involving headache and dizziness, are generally transient and rapidly resolve after the stimulation period; epileptic seizures during the stimulation have been reported, generally under predisposing conditions, but no recurrence of seizures has been reported so far. 45 Contraindications to rTMS, similar to those for MRI imaging, require the use of a safety questionnaire before. Additional concerns of rTMS involve the possibility of hearing loss from ear damage by the noise of the stimulus click, which can be reduced by the use of earplugs for patients and operators. Persistent adverse events for tDCS include persistent events consist of skin burns and mania or hypomania in patients with depression.
Open issues
The therapeutic application of NIBS is limited by individual variability in response, even in healthy subjects. For instance, genetic polymorphisms of the brain-derived neurotrophic factor (BDNF), a neurotrophin involved in activity-dependent modulation of synaptic plasticity, significantly influence the extent of plastic changes induced by NIBS in humans. 46 The issue becomes trickier when considering MS pathology. Cortical synaptic plasticity can be significantly influenced by drugs active on the central nervous system, often administered, particularly in pwMS with the progressive course, for the treatment of spasticity or neuropathic pain. For example, benzodiazepines and baclofen reduce the amount of LTP-like and longterm depression (LTD)-like changes by NIBS techniques, possibly due to increased inhibitory postsynaptic activity. 46 The previous history of synaptic activity may also influence the response to NIBS 46 and neuroinflammation may alter both glutamatergic signaling and GABAergic transmission, as from the animal models of MS described above. Similarly, in pwMS, disease-related alteration of LTP-like plasticity may limit subsequent functional recovery after an acute relapse. 47 On these premises, the effect of NIBS is likely to vary according to the disease phase. Furthermore, current flow induced by NIBS techniques seems to differ in patients in relation with the volume and topography of lesions. 34 
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